Drug intelligence / Profile preview

U3-1565

Development stage: Phase 1
Lead developer: Daiichi Sankyo
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

U3-1565 is a fully human monoclonal antibody that targets heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGF family and ligand for EGFR and HER4. By binding to HB-EGF, U3-1565 inhibits its activity, which mediates angiogenesis through induction of vascular endothelial growth factor (VEGF-A). The drug was developed as an antineoplastic agent with preclinical anti-tumor and anti-angiogenesis activity. Clinical studies in patients with advanced solid tumors demonstrated safety, tolerability, pharmacokinetics, and some clinical activity; however, development was discontinued after phase 1 trials in colorectal cancer and other solid tumors[1][2][4][5].

Other names: anti-HB-EGF antibody

Targets

HBEGF (Heparin-binding EGF-like growth factor)

Beyond the preview

Go deeper on U3-1565.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on U3-1565.

Explore the full profile